Helicobacter Pylori Non-Invasive Testing Market to Expand Modestly with 9.3% During Period 2020-2026

Helicobacter Pylori infection, or H. Pylori, is the most prevalent bacterial infection, affecting the digestive tract and inner stomach lining.
 
 
Spread the Word
Listed Under

Tag:
Diagnostics

Industry:
Medical

Location:
Dublin 2 - Dublin - Ireland

DUBLIN 2, Ireland - May 14, 2020 - PRLog -- Helicobacter Pylori infections, or H. Pylori, are the most common types of infections affecting the digestive tract. The infection is prevalent among half of the world's population, who typically reside in unhygienic and poor sanitary conditions. It is the most common reason for dyspepsia, peptic ulcers and gastric adenocarcinoma.

In view of this, the demand for H. Pylori testing has increased, particularly non-invasive molecular techniques such as real-time PCR and Chemiluminescence Immunoassay (CLIA). The Helicobacter Pylori Non-Invasive Testing market is anticipated to register a moderate CAGR of 3.9% during the forecast period (2020-2026).

Key Takeaways of Global H. Pylori Non-Invasive Testing Market Study:

• By test type, the urea breath test segment is anticipated to hold a major chunk of the market, amounting to over two-fifth. High rate of accuracy in detecting the presence of H. Pylori and usefulness in evaluating post-treatment status are poised to leverage this segment.
• The Stool Antigen Test segment shall comprise the 2nd largest share of the global H. Pylori Non-invasive testing market, accounting for over 40%. Simplicity and accuracy of the test in determining infection is anticipated to drive the segment's growth.
• By test method, the Laboratory-based Tests segment shall generate high demand. The ability to test a large number of patients and their accurate and precise methodologies are anticipated to be the key drivers. The segment is foreseen to hold more than three-fifth of the market.
• By end-use, diagnostic labs are anticipated to be the most lucrative, capturing almost half of the total market. Key pharmaceutical companies partnering to provide wider reach for testing H. Pylori are anticipated to drive the market. For instance, in 2010, Meridian Bioscience entered into an agreement with DiaSorin S.p.A to develop infectious disease tests for use on its LIAISON automated instrumets.
• North America is anticipated to be the most promising market. This is attributed to changing healthcare reforms. These reforms have directed organizations to abandon serology tests due to its uncertainty in predicting infections and to switch to urea-based and stool antigen testing. The region is anticipated to hold 31.1% of the H. Pylori testing market.
• Asia-Pacific shows modest growth opportunities, owing to increased awareness about H. Pylori infections and government efforts to contain the risk of infections. Moreover, H. Pylori testing among communities with gastric cancer has increased, preventing further risks. The region is anticipated to expand modestly at a CAGR of 4.5%.

Read Report here- https://www.factmr.com/report/4774/helicobacter-pylori-hp...

Contact
Fact.MR
***@factmr.com
End
Email:***@factmr.com Email Verified
Tags:Diagnostics
Industry:Medical
Location:Dublin 2 - Dublin - Ireland
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fact.MR PRs
Most Viewed
Top Monthly News



Like PRLog?
9K2K1K
Click to Share